1. RA190 Small Molecule Proteasome Inhibitor for Cancer Therapy

2. Targeting the proteasome… Proteasomal degradation of tumor suppressor proteins is found in many cancers apoptosis arrest sustained cell proliferation

3. RA190: Reduced toxicity novel mechanism of action overcomes drug resistance Preferential targeting of transformed cells Current proteasome inhibitors: –grave side effects –disease resistance

4. Mechanism Of Action Binds to ubiquitin receptor RPN13 RPN13 is part of the 19S Regulatory Cap Responsible for removing Ub from target proteins Proteasome inhibited Misfolded protein buildup

6. The Drug Orally available Promising toxicity profile Works on tumors resistant to bortezumib Active against cervical and ovarian cancer, and Multiple Myeloma

7. The Business What we do: Find cancer cure Who we are: CanCure Inc. “Because we CanCure cancer*!” * By cancer, we mean cervical and ovarian cancer, and multiple myeloma.

8. The Team Looking to build a highly dedicated, talented, and experienced management team: Looking for: CEO: preferably with product launch experience CFO CMO CRO VPs Etc…

9. The Market Ovarian cancer: 17 th most common cancer 21,980 estimated new cases in 2014 14,270 deaths Cervical cancer: 21 st most common cancer 12,360 estimated new cases in 2014 4,020 deaths Multiple myeloma: 14 th most common cancer 24,050 estimated new cases in 2014 11,090 deaths *From NCI SEER statistics 2014

10. Financial Projections

11. Growth Strategy Develop companion diagnostic test for RA190 Explore RA190 in other cancers Exit Strategy Sell company to large pharma